Expression of CD30 (44% vs. 14%, p < 0.0001), p50 (61% vs. 34%, p = 0.0124) and phosphorylated signal transducer and activator of transcription 3 (pSTAT3) (39% vs. 16%, p = 0.0079) were more commonly observed than the EBV negative de novo DLBCL patients. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.